Kornimate/medical-research-clean huggingface dataset:
the effect of proprioceptive neuromuscular facilitation and mirror therapy on range of motion, pain, functionality, kinesophobia and quality of life in patients with upper extremity burns

Conditions: Burn; Arm

Summary: purpose of the study; the aim of this study was to investigate the effect of two different exercise programs on joint patency, pain, functionality, kinesophobia and quality of life in upper extremity burn patients. lütfi kırdar training and research hospital burn and wound center and unilateral upper extremity burns will consist of individuals aged 18-65 years. 48 burn patients who volunteered to participate in the study will be included in the study. demographic information of the cases will be recorded. joint range of motion and pain will be evaluated with the visual analogue scale (vas) before and after the treatment program. disabilities of the arm, shoulder and hand (dash) questionnaire will be used to evaluate upper extremity functions. tampa kinezophobia questionnaire will also be used for kinesiophobia. to evaluate the quality of life, burn-specific health scale developed for burn patients will be used.

joint range of motion of the subjects will be measured with a goniometer. pain will be evaluated with the visual analogue scale (vas). in order to evaluate the upper extremity functions, the validity and reliability of the disabilities of the arm, shoulder and hand (dash) questionnaire, conducted by tülin düger et al. the tampa kinezophobia questionnaire, which has been validated and validated in 2011, will be used for kinesiophobia. the burn-specific health scale developed for burn patients will be used to evaluate the quality of life. the validity and reliability study of the questionnaire was conducted by mehmet adam et al.

Eligibility criteria:
inclusion criteria: -18-65 years of age, -the unilateral upper extremity burn, -the understanding of the given information, the application of mirror therapy and the ability to accurately express the level of pain that prevents cognitive, affective and verbal communication there is no problem and no visual impairment, - turkish reading and writing, - paralysis, plaster, etc. that will prevent movement in the extremity opposite the burned extremity. to be cognitive enough to understand the surveys, - agreeing to participate voluntarily in the study - exclusion criteria: * t.c. ministry of health kartal lütfi kırdar training and research hospital burn and wound center treated patients between the ages of 0-18, * burn patients who refused to participate in the study, - patients with bilateral upper extremity burns

Keywords: burn, physiotherapy
role of activin a (acta) in the human cancer cachexia

Conditions: Colorectal Cancer; Lung Cancer

Summary: the goal of the investigators study is to investigate the role of a hormone named activin a (acta) in the development of the skeletal muscle atrophy caused by cancer. according to the investigators hypothesis, acta could be released by the tumor and activate a muscle atrophy gene program. to answer this question, the investigators plan first to compare circulating levels of acta in cancer patients with and without cachexia. in a second step, the investigators would like to assess whether acta circulating levels are predictive for the development of cachexia and short survival.


Eligibility criteria:
inclusion criteria: * 18-year-old or older * colorectal or lung cancer demonstrated by histology or cytology * new diagnosis or new recurrence * expected survival more than 3 months * no previous history of other cancer in the last 5 years * no pregnancy or lactation * signed informed consent exclusion criteria: * non-caucasian * major digestive malabsorption * major depression * artificial nutrition * height doses of steroids (\>1 mg/kg hydrocortisone equivalent) * hyperthyroidism * other causes of malnutrition * expected survival less than 3 months * severely impaired walking * anticoagulants or antiplatelet therapy * disability or medical condition which might prevent the compliance to the protocol * any conditions which may prevent the compliance to the protocol * performance status ecog \> ou = 4 * participation to other clinical studies
investigation of the effect of n acetylcysteine against anti-tuberculosis drugs induced liver toxicity

Conditions: Hepatitis; Tuberculosis

Summary: tuberculosis is one of the major health problems in developing countries. isoniazid, rifampin and pyrazinamide, the first line drugs used for tuberculosis chemotherapy, are associated with hepatotoxicity. the rate of hepatotoxicity has been reported to be much higher in developing countries compared to that in advanced countries with a similar dose schedule. oxidative stress has proposed as one of the mechanisms responsible for anti-tuberculosis drugs induced hepatic injury. the oxidative stress is closely associated with decrease of glutathione levels. in the present study n acetylcysteine, a precursor of glutathione, was investigated for hepatoprotective effect against anti-tuberculosis drugs induced liver injury.


Eligibility criteria:
inclusion criteria: * two sputum specimens positives for tubercle bacilli on direct smear microscopy * no previous anti-tb chemotherapy higher than two weeks * aged 60 years and over * agreement to participate in the study exclusion criteria: * alcohol consumption * viral disease (hepatitis,...) * abnormal pretreatment lft level * chronic disease (liver and kidney disease, asthma,...) * additional hepatotoxic drug use * hiv positive * liver tb * patient in a moribund state * hemoptysis
efficacy, safety and tolerability of pf-06649751 in parkinson's disease patients with motor fluctuations

Conditions: Parkinson Disease

Summary: the purpose of this study is to evaluate the efficacy, safety and tolerability of pf-06649751 in parkinson's disease patients who experience motor-fluctuations.

the study has a randomized, double-blind, placebo-controlled parallel group design. approximately 198 subjects will be randomized to 5 treatment groups. each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.

Eligibility criteria:
inclusion criteria: * females of non-childbearing potential and/or male subjects between the ages of 40 and 85 years, inclusive. * clinical diagnosis of parkinson's disease. * able to refrain from any parkinson's disease medication not permitted by the protocol. exclusion criteria: * female of childbearing potential * history or presence of atypical parkinsonian syndrome. * history of surgical intervention for parkinson's disease. * severe acute or chronic medical or psychiatric condition or laboratory abnormality. * any condition possibly affecting drug absorption. * participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.

Keywords: parkinson disease motor fluctuation
phase i study of continuous administration of salvianolic acid a tablet

Conditions: Diabetes

Summary: salvianolic acid a has a variety of pharmacological effects, such as: anti-oxidation, scavenging oxygen free radicals, anti-fibrosis, anti-myocardial ischemia, anti-coagulation, anti-thrombosis, anti-tumor, etc. professor du guanhua, at institue of materia medica, chinese academy of medical sciences, first discovered that salvianolic acid a can alleviate diabetic complications and improve patients' quality of life. with the support of major national science and technology projects, the preclinical research work of salvianolic acid a was completed, and the application was approved by the state food and drug administration (clinical approval no.: 2016l06293).the purpose of this study is to assess the safety,tolerability, and pharmacokinetics (pk) of an extended dosing regimen ofsalvianolic acid a: open label, continuous subcutaneous infusion for 7 days were tested as ascending doses of salvianolic acid a from 90mg up to 180 mg.

this was a phase i repeated incremental doses study in healthy volunteers. a total of 24 subjects was planned to be enrolled. this was performed according to a double blind, randomized, placebo controlled design and included two sequential dose groups of repeat doses. each group enrolled 12 subjects on salvianolic acid a or placebo (ratio 9 experimental: 3 placebo) and received salvianolic acid a or placebo twice daily (90mg) or daily (180mg) for 7 days, and follow-up to 3 or 4 days.

Eligibility criteria:
inclusion criteria: * 1) gender: male or female, healthy volunteers; 2) age: 18\~45 years old; 3) weight: male subjects need to weigh ≥ 50kg, female subjects should have ≥ 45kg, body mass index \[bmi = weight (kg) / height 2 (m2)\] in the range of 19 \~ 25 kg / m2; 4) subjects must give informed consent to the trial prior to the trial and voluntarily sign a written informed consent form; 5) the subject is able to communicate well with the investigator and is able to complete the trial in accordance with the protocol. exclusion criteria: * (1) hepatitis b surface antigen, hepatitis c virus, human immunodeficiency virus and syphilis positive; (2) alcoholics; (3) subjects who took any drug or long-term use of drugs within 2 weeks before screening (4) blood donors within 3 months prior to the trial; (5) participated in any drug clinical trial within 3 months prior to screening; (6) had a clear history of allergic disease; (7) had central nervous system, cardiovascular systematic, kidney, liver, digestive tract, lung disease, metabolic and skeletal muscle system with a clear history or other significant disease; (8) pregnant, lactating women; (9) other factors not suitable for participation in the study.
intrapatient comparison of urinary radioactivity following piflufolastat (18f) and flotufolastat (18f) pet in men with low psa biochemical recurrence of prostate cancer following radical prostatectomy

Conditions: Prostate Cancer

Summary: intrapatient comparison of urinary radioactivity following piflufolastat (18f) and flotufolastat (18f) pet in men with low psa biochemical recurrence of prostate cancer following radical prostatectomy

this is a multi-center, prospective intra-patient comparator study of urinary radioactivity (standardized uptake values \[suv\]) following both piflufolastat (18f) and flotufolastat (18f) positron emission tomography (pet) in patients with low prostate-specific antigen (psa; ≤0.5 ng/ml) biochemical recurrence (bcr) of prostate cancer following radical prostatectomy (rp).

Eligibility criteria:
inclusion criteria: * male ≥18 years of age at visit 1 (screening). * documented history of localized adenocarcinoma of the prostate with prior curative intent treatment with rp and undetectable psa post-surgery, experiencing bcr of prostate cancer. * at least 6 months must have elapsed after rp. * low psa bcr defined as psa ≤0.5 ng/ml. * scheduled by their treating physician to receive a psma (18f) pet scan. * written informed consent obtained from the patient and ability for the patient to comply with the requirements of the study. exclusion criteria: * patients with any medical condition or circumstance (including receiving an ip) that the investigator believes may compromise the data collected or lead to a failure to fulfill the study requirements. * patients who are planned to have an x-ray contrast agent or any other pet radiotracer within 24 hours prior to either psma pet scan. * patients who have already received a piflufolastat (18f) pet scan prior to providing informed consent for this study. * patients participating in an interventional clinical trial within 30 days and having received an ip within five biological half-lives prior to either of the psma pet scans in this study. * patients with known hypersensitivity to the active substance or to any of the excipients of piflufolastat (18f) or flotufolastat (18f). * patients who have previously undergone a cystectomy or have renal failure, or have other conditions that may significantly affect urinary output, as judged by the investigator. * patients who have already received salvage therapy.
a prospective study to collect high-quality documentation of bleeds, health-related quality of life (hrqol), and safety outcomes in patients with hemophilia a treated with standard-of-care treatment

Conditions: Hemophilia A

Summary: this non-interventional study will prospectively collect detailed, high-quality documentation of bleeds, hrqol, and safety in patients with hemophilia a with or without fviii inhibitors treated according to local routine clinical practice (receiving fviii replacement or bypassing agents as either episodic or prophylactic treatment). actual patients will be enrolled from routine clinical practice in this observational study.


Eligibility criteria:
inclusion criteria: * cohort a: patients greater than or equal to (\>/=) 12 years of age at time of informed consent * cohort a: diagnosis of congenital hemophilia a of any severity and documented history of high-titer inhibitor (that is, \>/= 5 bethesda units \[bu\]) * cohort b: pediatric patients less than (\<) 12 years of age * cohort b: diagnosis of congenital hemophilia a of any severity and documented history of high-titer inhibitor (that is, \>/=5 bu) * cohort c: patients \>/=12 years of age * cohort c: diagnosis of congenital hemophilia a and fviii activity \<1 percent (%) * cohort c: no prior history of a positive inhibitor against fviii exclusion criteria: * prior ro5534262 (not applicable if patient agrees that prior ro5534262 will preclude participation in a future investigational ro5534262 study) * bleeding disorder other than congenital hemophilia a * ongoing (or planned during the study) immune tolerance induction therapy with fviii or fviii prophylaxis if currently/previously exposed to an inhibitor * previous or concomitant thromboembolic disease * known human immunodeficiency virus (hiv) infection with cluster of differentiation (cd) 4 count \<200 cells per microliter (cells/mcl)
pharmacodynamic and pharmacokinetic variability of a basal insulin (0000-168)

Conditions: Diabetes

Summary: the purpose of this study is to evaluate whether the within-subject variation in duration of action and time-action profile of glargine measured by isoglycemic clamp will be below prespecified levels.


Eligibility criteria:
inclusion criteria: part 1: * patient is a male between 18 to 45 years of age (inclusive) at the prestudy (screening) visit * patient has a clinical diagnosis of type 1 diabetes * patient must have been treated with insulin since diagnosis and be on a stable dose of insulin * patient has a body mass index (bmi) of \ 18 kg/m2 * patient has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months part 2: * subject is a male between 18 to 45 years of age at the prestudy (screening) visit * subject has a body mass index (bmi) of \<=25 kg/m\^2 * subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months exclusion criteria: part 1: * patient has a history of stroke, chronic seizures, or major neurological disorder * patient has currently active and untreated clinically significant endocrine, cardiovascular, hematological, hepatic, renal, respiratory, or genitourinary abnormalities or diseases * patient has a history of hypertension requiring treatment * patient has a history of neoplastic disease within the past 5 years * patient is currently being treated with, or has a history of treatment with any oral antihyperglycemic agent * patient has a history of significant multiple and/or severe allergies part 2: * subject has a history of stroke, chronic seizures, or major neurological disorder * subject has a history of hypertension requiring treatment * subject has a history of neoplastic disease within the past 5 years * subject has history of diabetes (type 1, type 2 or steroid-induced) or family history of diabetes mellitus * subject has a history of hypersensitivity to glargine or any of its inactive ingredients

Keywords: insulin
probiotic intervention with elderly subjects

Conditions: Intestinal C. Difficile

Summary: the study objective is to evaluate the effect of probiotic on faecal clostridium difficile levels of elderly subjects.

the study objective is to evaluate the effect of a probiotic lactobacillus strain in lowering the levels of clostridium difficile in the intestine of elderly subjects. in addition, the nutritional and general health status will be assessed using validated health related questionnaires. bowel function and prevalence of infections will be followed throughout the intervention period. the study population consists of elderly home inhabitants. the study will be conducted as a double-blind placebo-controlled trial.

Eligibility criteria:
inclusion criteria: * elderly subjects * no acute infection at recruitment exclusion criteria: * antibiotic treatment 1 month prior to beginning of study * less than 6 month life expectancy

Keywords: elderly probiotic bowel function pathogen constipation diarrhoea subclinical levels
nutrition education program for postoperative patients with gastric cancer

Conditions: Gastric Cancer; Nutrition Disorders

Summary: using randomized control study, explore the effect of standardized nutrition education program on the nutrition status and life quality of patients with gastric cancer after surgery.


Eligibility criteria:
inclusion criteria: * patients are diagnosed with gastric cancer and receive operation. * patients need nutrition support treatment * informed consent. exclusion criteria: * critical patients or stage iv * patients with severe hepatic cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, intestinal obstruction, stroke. * unconscious or psychiatric patients * patients with communication problems

Keywords: gastric cancer nutrition health education
clinical and molecular characterization of axial psoriatic arthritis (psa), a pilot study

Conditions: Psoriatic Arthritis

Summary: objectives: to identify a candidate set of biomarkers specific to axpsa. overview: clinical and imaging characterization of psa patients will be combined with extensive molecular assessment of both liquid and tissue compartments to identify biomarkers which differentiate psa patients with and without axial involvement


Eligibility criteria:
inclusion criteria: * persons with psa diagnosed by a consultant rheumatologist with disease duration of \> 3 months but \< 10 years with or without ibp. * adults between the ages 18 and 80 years, with joint disease onset after 16 years of age * patients able to understand and complete consent procedures * study participants must have psa, meet caspar criteria, and must have active disease as defined by the treating rheumatologist, including an evaluable psoriatic skin lesion amenable to 6mm punch skin biopsy. o psoriasis should be diagnosed by a consultant rheumatologist or dermatologist. * study participants must have been on consistent therapy for their psa for the past 90 days * study participants must be naïve to biological treatment and targeted synthetic dmard treatment (examples: jak inhibitors, apremilast) exclusion criteria: * • persons with musculoskeletal (peripheral or axial) symptoms for \>10 years * persons with planned major surgery (e.g., joint replacement) within the duration of the collection of data for the study * persons with a history of chemotherapy, radiation therapy or immunotherapy for cancer in the preceding 5 years. * persons with ongoing cancer (not excluding non-melanoma skin, cervical/breast in-situ carcinoma) but those fully recovered from an episode of cancer (in remission for more than 5 years) may be included at the discretion of the patient's treating rheumatologist. * persons with an active severe or serious infection * patients with non-severe infection at the discretion of the investigator * persons with other concomitant disorders incompatible with study (at discretion of investigator).
analgesic efficacy of surgeon-administered transversus abdominis plane blocks for caesarean section.

Conditions: Cesarean Section Complications; Pain, Postoperative

Summary: the purpose of this research study is to evaluate whether or not adding a transversus abdominis plane block (tap block) improves pain control for patients having a cesarean section. a tap block is a type of nerve block where at the end of the surgery an injection of a long acting local anesthetic is made into the abdominal wall. in studies in patient's having other abdominal surgeries this has reduced the amount of narcotics patients need for pain control. this may also led to patients being more active after surgery and maybe spending less time in hospital.

randomized clinical trial of transversus abdominis plane block (tap block) at cesarean section.

Eligibility criteria:
inclusion criteria: * asa status ii to iii * all patients undergoing elective cs under regional anesthesia at any gestational age. exclusion criteria: * - known drug allergy to local anesthetics * planned general anesthetic * nsaid use contraindicated post partum * chronic pain disorder or chronic narcotic use/dependence * planned vertical abdominal incision * planned cesarean hysterectomy. * placenta previa or suspected placenta accreta
intra-articular vancomycin powder in knee and hip arthroplasty

Conditions: Infection

Summary: the purpose of this study is to compare infection rates when patients, elected for primary or aseptic revision tha / tka, have a single intravenous antibiotic dose versus one single intravenous antibiotic dose in combination with intra-articular antibiotics. this is a prospective, randomized clinical survey on selected outcome measurements on 1834 subjects who will be recruited in a period of about 2 years.

group a: patients receiving single dose of iv cefazolin 10-60 minutes before incision. group b: patients receiving a single dose of iv cefazolin 10-60 minutes before incision + a single dose of intra-articular vancomycin powder before articulation (hip or knee) closure.

Eligibility criteria:
inclusion criteria: * standard criteria for the implantation of primary total hip or knee replacement * revision of an aseptic tha or tka. * adults \>18 years of age * diagnosis of osteoarthrosis (oa), osteonecrosis (on), arthritis; or aseptic loosening of tha/tka. * subject is willing to consent to participate in the study * subject is available for follow-up through at least 2 years * subject has met acceptable preoperative medical clearance and is free of or treated for medical conditions that would pose excessive operative risk. * subject who are fluent in english and / or french and able to understand their role in the study exclusion criteria: * active, local infection or systemic infection. * participation in any other pharmaceutical, biologic or medical device clinical investigation * subjects with known allergy to vancomycin * subjects unable to consent * patient with skin pathology

Keywords: vancomycine hip arthroplasty knee arthroplasty hip revision arthroplasty knee revision arthroplasty